A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Hoffmann-La Roche
Bristol-Myers Squibb
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Fudan University
Shanghai JMT-Bio Inc.
Shanghai Zhongshan Hospital
University of Cincinnati
CSPC Megalith Biopharmaceutical Co.,Ltd.
RemeGen Co., Ltd.
Seattle Project Corporation
NRG Oncology
InnoPharmax Inc.
University of Virginia
University of Birmingham
Australasian Gastro-Intestinal Trials Group
Gruppo Oncologico del Nord-Ovest
Tyme, Inc
CancerCare Manitoba
Ono Pharmaceutical Co. Ltd
RemeGen Co., Ltd.
Assiut University
Shanghai University of Traditional Chinese Medicine
Qilu Pharmaceutical Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sorrento Therapeutics, Inc.
Hebei Medical University
Ruijin Hospital
ASLAN Pharmaceuticals
Ruijin Hospital
Ruijin Hospital
Medstar Health Research Institute
Odense University Hospital
Hebei Medical University
Hutchmed
University of Birmingham
Sichuan Provincial People's Hospital
Hospital San Carlos, Madrid
Velindre NHS Trust
State Key Laboratory of Cancer Biology
Instituto Nacional de Cancer, Brazil
Shandong Cancer Hospital and Institute
The Netherlands Cancer Institute
Merrimack Pharmaceuticals
Medical Research Council
Ruijin Hospital
GBG Forschungs GmbH
Fudan University
Columbia University
National Cancer Institute (NCI)